Rabies Vaccine BP is an inactivated vaccine indicated for pre-exposure and post-exposure prophylaxis against rabies in all age groups.
Rabies is an acute viral infection causing inflammation of the spinal cord and the brain1 that leads to the deaths of tens of thousands of people worldwide.2 In developing countries, where it is most often transmitted by dogs, rabies is still considered a major public health concern.2
Transmitted through the saliva of an infected mammal, usually via a bite, scratch or lick3 The incubation period for the disease is usually 2-3 months but can be anything from a week to 1 year.2
Vaccination may be considered for all travellers who will be living or visiting endemic areas especially if:3
visiting areas where access to post-exposure treatment and medical care is limited
they are planning higher risk activities such as cycling and running
they are planning to stay for more than one month
Rabies Vaccine BP can be used to help provide pre-exposure and post-exposure prophylaxis.
Rabies vaccine ≥ 2.5 IU/ml (inactivated)
1 ml prefilled diluent syringe + vial of lyophilised powder
3 doses at 0, 7 and 21 or 28 days.
For those at continued risk, booster doses should be given in line with official recommendations.
No lower or upper age limit listed
Sanofi Pasteur is committed to providing you and your patients with a comprehensive range of support materials, including disease awareness patient leaflets and in-surgery display items.
• Simply visit https://sanofi.medisa.com
• Select the user group which best describes your role in your organisation
• Narrow your search by selecting the appropriate disease area
• Select which materials you would like to receive and how many
• Log-in or register to create an account
• Confirm your order
Date of preparation: September 2020 | MAT-GB-2001793(v2.0)